Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty
Provided By PR Newswire
Last update: Jun 25, 2025
*Hoth Therapeutics and Silo Pharma Launch Joint Venture to Commercialize VA-Invented Obesity Drug Targeting $100B+ Global Market
Exclusive License from U.S. Department of Veterans Affairs to Advance GDNF-Based Therapy for Obesity and Fatty Liver Disease
Read more at prnewswire.comNASDAQ:SILO (10/1/2025, 10:01:17 AM)
0.6975
+0.01 (+1.09%)
NASDAQ:HOTH (10/1/2025, 10:01:45 AM)
1.6122
-0.01 (-0.48%)
Find more stocks in the Stock Screener
SILO Latest News and Analysis
